Search

Displaying results 761 - 770 of 3180 in total
  1. Drug

    Tetraethylammonium

    go.drugbank.com/drugs/DB08837
    Investigational

    Tetraethylammonium is an experimental drug with no approved indication or marketed formulation.

  2. Drug

    PF-04995274

    go.drugbank.com/drugs/DB12675
    Investigational

    Pf 04995274 is under investigation in clinical trial NCT01193062 (Study In Healthy Subjects To Evaluate The Changes In The Protein sAPP-Alpha In Cerebrospinal Fluid Following A Single Oral Dose Of PF-04995274

  3. Drug

    PF-06751979

    go.drugbank.com/drugs/DB15105
    Investigational

    PF-06751979 is under investigation in clinical trial NCT03126721 (The Study is to Evaluate the Effect of Multiple Doses PF-06751979 on the Pharmacokinetics of Midazolam in Healthy Adults).

  4. Drug

    Oxamniquine

    go.drugbank.com/drugs/DB01096
    Approved

    Oxamniquine causes worms to shift from the mesenteric veins to the liver where the male worms are retained; the female worms return to the mesentery, but can no longer release eggs.

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2D6 Inhibitors
  5. Drug

    Trimethobenzamide

    go.drugbank.com/drugs/DB00662
    ApprovedInvestigational

    In dogs pretreated with trimethobenzamide HCl, the emetic response to apomorphine is inhibited, while little or no protection is afforded against emesis induced by intragastric copper sulfate.

    Synonyms: N-[[4-(2-dimethylaminoethoxy)phenyl]methyl]-3,4,5-trimethoxybenzamide
  6. Drug

    Protego-PD

    go.drugbank.com/drugs/DB18279
    Experimental

    Protego-PD is a post-delivery placental extract.

    Synonyms: Protego-PD
  7. Drug

    Polyethylene glycol 400

    go.drugbank.com/drugs/DB11077
    ApprovedInvestigational

    Polyethylene glycols (PEGs) are products made of condensed ethylene oxide and water that can contain various derivatives and have various functions. Because many PEG types are hydrophilic, they are favorably used as enhancers of penetrat...

    Mixtures: Hydration PF, Systane Hydration PF Preservative FreeCategories: P-glycoprotein inhibitors
  8. Drug

    Gantenerumab

    go.drugbank.com/drugs/DB12034
    Investigational

    Despite the clear association of Aβ aggregation with AD, treatments aimed at preventing Aβ aggregation or removing pre-existing Aβ plaques have shown little to no clinical benefit thus far and remain controversial

  9. Drug

    Bosutinib

    go.drugbank.com/drugs/DB06616
    ApprovedInvestigational

    -alkoxy-3-quinolinecarbonitrile that functions as a potent, dual SRC and ABL tyrosine kinase inhibitor indicated for chronic myelogenous leukemia (CML), specifically Philadelphia chromosome-positive (Ph … [A6901,A17961] Bosutinib was first approved by the FDA in 2012 for the treatment of adult chronic, accelerated, or blast-phase Ph+ CML with resistance or intolerance to prior therapy.

    Categories: P-glycoprotein substrates, Cytochrome P-450 Substrates
  10. Drug

    Bepridil

    go.drugbank.com/drugs/DB01244
    ApprovedWithdrawn

    It is no longer marketed in the United States, as it has been implicated in causing ventricular arrhythmias (ie. Torsade de pointes).

    Categories: P-glycoprotein inhibitors, Cytochrome P-450 SubstratesSynonyms: .-((2-METHYLPROPOXY)METHYL)-N-PHENYL-N-(PHENYLMETHYL)-, 1-(2-(N-BENZYLANILINO)-1-(ISOBUTOXYMETHYL)ETHYL)-PYRROLIDINE